Zhangzhou Pientzehuang Pharmaceutical., Ltd

XSSC:600436 Stock Report

Market Cap: CN¥140.6b

Zhangzhou Pientzehuang Pharmaceutical Valuation

Is 600436 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600436 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600436 (CN¥233.11) is trading below our estimate of fair value (CN¥234.16)

Significantly Below Fair Value: 600436 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600436?

Key metric: As 600436 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600436. This is calculated by dividing 600436's market cap by their current earnings.
What is 600436's PE Ratio?
PE Ratio45.7x
EarningsCN¥3.08b
Market CapCN¥140.64b

Price to Earnings Ratio vs Peers

How does 600436's PE Ratio compare to its peers?

The above table shows the PE ratio for 600436 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.7x
000538 Yunnan Baiyao GroupLtd
23.8x11.3%CN¥102.3b
600085 Beijing Tongrentang
34.3x15.8%CN¥55.9b
600196 Shanghai Fosun Pharmaceutical (Group)
33.6x30.1%CN¥63.7b
600276 Jiangsu Hengrui Medicine
59.2x14.8%CN¥322.3b
600436 Zhangzhou Pientzehuang Pharmaceutical
45.7x15.9%CN¥140.6b

Price-To-Earnings vs Peers: 600436 is expensive based on its Price-To-Earnings Ratio (45.7x) compared to the peer average (37.7x).

Price to Earnings Ratio vs Industry

How does 600436's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600436 45.7xIndustry Avg. 32.0xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600436 is expensive based on its Price-To-Earnings Ratio (45.7x) compared to the CN Pharmaceuticals industry average (32x).

Price to Earnings Ratio vs Fair Ratio

What is 600436's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600436 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.7x
Fair PE Ratio33x

Price-To-Earnings vs Fair Ratio: 600436 is expensive based on its Price-To-Earnings Ratio (45.7x) compared to the estimated Fair Price-To-Earnings Ratio (33x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600436 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥233.11
CN¥277.61
+19.1%
19.1%CN¥358.00CN¥175.00n/a11
Nov ’25CN¥237.30
CN¥274.88
+15.8%
19.5%CN¥358.00CN¥175.00n/a11
Oct ’25CN¥258.49
CN¥264.10
+2.2%
17.9%CN¥358.00CN¥170.00n/a11
Sep ’25CN¥208.59
CN¥264.10
+26.6%
17.9%CN¥358.00CN¥170.00n/a11
Aug ’25CN¥210.10
CN¥272.62
+29.8%
17.7%CN¥358.00CN¥182.00n/a10
Jul ’25CN¥206.23
CN¥285.76
+38.6%
16.0%CN¥358.00CN¥190.00n/a10
Jun ’25CN¥227.00
CN¥277.73
+22.3%
14.7%CN¥328.00CN¥190.00n/a9
May ’25CN¥237.24
CN¥285.63
+20.4%
15.7%CN¥336.00CN¥190.00n/a9
Apr ’25CN¥234.42
CN¥295.86
+26.2%
14.4%CN¥336.00CN¥195.00n/a10
Mar ’25CN¥223.36
CN¥295.86
+32.5%
14.4%CN¥336.00CN¥195.00n/a10
Feb ’25CN¥191.21
CN¥299.86
+56.8%
12.5%CN¥336.00CN¥202.00n/a10
Jan ’25CN¥241.99
CN¥302.86
+25.2%
13.2%CN¥350.00CN¥202.00n/a10
Dec ’24CN¥252.11
CN¥302.86
+20.1%
13.2%CN¥350.00CN¥202.00n/a10
Nov ’24CN¥251.20
CN¥302.86
+20.6%
13.2%CN¥350.00CN¥202.00CN¥237.3010
Oct ’24CN¥275.21
CN¥315.40
+14.6%
13.3%CN¥370.00CN¥200.00CN¥258.4911
Sep ’24CN¥278.03
CN¥315.40
+13.4%
13.3%CN¥370.00CN¥200.00CN¥208.5911
Aug ’24CN¥289.78
CN¥318.22
+9.8%
14.7%CN¥390.00CN¥205.00CN¥210.1010
Jul ’24CN¥286.36
CN¥320.80
+12.0%
14.9%CN¥390.00CN¥210.00CN¥206.239
Jun ’24CN¥298.00
CN¥319.68
+7.3%
15.7%CN¥390.00CN¥200.00CN¥227.009
May ’24CN¥271.93
CN¥305.26
+12.3%
15.6%CN¥358.00CN¥200.00CN¥237.249
Apr ’24CN¥284.38
CN¥302.09
+6.2%
18.8%CN¥360.00CN¥200.00CN¥234.427
Mar ’24CN¥314.58
CN¥328.32
+4.4%
28.4%CN¥550.00CN¥200.00CN¥223.369
Feb ’24CN¥311.14
CN¥328.88
+5.7%
28.1%CN¥550.00CN¥205.00CN¥191.219
Jan ’24CN¥288.46
CN¥324.43
+12.5%
28.3%CN¥550.00CN¥205.00CN¥241.999
Dec ’23CN¥258.99
CN¥329.98
+27.4%
28.4%CN¥550.00CN¥205.00CN¥252.119
Nov ’23CN¥242.63
CN¥331.23
+36.5%
30.0%CN¥550.00CN¥205.00CN¥251.208

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥51.9b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥32.72

7D

7.3%

1Y

15.1%

China Resources Sanjiu Medical & Pharmaceutical

CN¥57.9b

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

999

CN¥45.11

7D

-1.3%

1Y

19.5%

China Resources Sanjiu Medical & Pharmaceutical

CN¥57.9b

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

999

CN¥45.11

7D

-1.3%

1Y

19.5%